Asia PR News

HELSINGBORG, Nov. 30 /PRNewswire-AsiaNet/ –

NOLabs AB, the Swedish medtech company developing innovative nitric
oxide-containing medical devices based on the NitroSense(R) Technology, today
reported that it has achieved another important milestone in the development of
a new line of products for wounds infected by MRSA-bacteria. MRSA stands for
Methicillin Resistant Staphylococcus aureus, a bacterium that is particularly
troublesome in hospital-acquired infections due to its resistance to several
traditional antibiotics.

In experiments performed at the Malmoe University Hospital in Sweden,
researchers showed that NOLabs’ technology has a promising ability to kill a
wide range of pathogens, including MRSA.

According to the US Centers for Disease Control and Prevention 126,000
hospitalisations are related to MRSA and 19,000 deaths are associated with
serious MRSA infections every year in U.S. hospitals. Patients at risk for
infection with MRSA include those with severe disease, recent surgery or
indwelling medical devices, such as urinary catheters.

Goran Beijer, CEO of NOLabs says: "The recent results show that we are on
the right track towards products with an enormous potential globally. The
anti-microbial effect of NO will be key in several products that will prevent
and/or treat infection depending on dosing. We are now accelerating our
development program and expect to have the first products on the market during
2008."

NOLabs’ NitroSense(R) Technology assures controlled, local delivery of
pure nitric oxide in a well-defined concentration range during a well-defined
time period. The main areas are prevention of catheter related urinary tract
infections, relief of neuropathic pain and wound care products with an anti-
bacterial effect.

For more information please visit our home page: http://www.nolabs.com.

NOLabs is a Swedish medtech company developing and marketing nitric oxide-
containing medical devices for various medical applications. Nitric oxide is a
natural substance, produced by the human body. Its physiological effects
include the control of local blood supply and the protection against microbes.
In particular, NOLabs focuses on prevention of infection and pain relief for
patients suffering from diabetes-related complications such as chronic wounds
and neuropathic pain. Another focus area is the prevention and treatment of
catheter-associated urinary tract infections. NOLabs has developed the
innovative, cost efficient and highly effective NitroSense(R)
Technology with a significant potential to address serious health issues that
impact the lives of over 100 million people.

Goran Beijer,
E-mail goran.beijer@nolabs.com,
Phone: +46-42-33-65-22;

Susanne Goransson,
E-mail: susanne.goransson@nolabs.com,
Phone: +46-42-33-65-30.

SOURCE NOLabs AB

CONTACT: Goran Beijer, goran.beijer@nolabs.com, +46-42-33-65-22, or
Susanne Goransson, susanne.goransson@nolabs.com, +46-42-33-65-30, both of
NOLabs AB

Web site: http://www.nolabs.com